Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
But read carefully, because the difference here is that this antibody test kit detects IgG/IgM - which are NOT specifically the Nabs!
Axim's "sauce" specifically looks for those antibodies that latch on to the COVID-19 HUMAN CELL RECEPTOR PROTEIN.
Nabs prevent infection by immediately latching onto and blocking this part of the virus and preventing it from ever being able to attach to the human cell.
"Their" test kit simply detects IgG and IgM antibodies, which grab onto different parts of the virus (and alert killer T-cells to "eat" the combination), but don't stop the "combination" from being able to latch onto a cell - if the combination is able to do so before a T-cell meets up with it and devours it.
Keep in mind that with natural immunity to COVID (ie: having actually contracted the virus before any type of "vaccination"), the human body makes about 20 to 22 different antibodies (IgGs and IgMs) to the virus - about 1 or 2 of which are actually the Nabs
Moving to what now appears to be the "more promising" line of products at this time, I went to the Vial Ophthalmology link ( https://vial.com/sites/ophthalmology/ ) and found this at the bottom:
Picture of Peter O'Rouke - click here
Peter O'Rourke (born January 3, 1966) is an American government official. He served as the acting United States Secretary of Veterans Affairs and VA Chief of Staff under President Donald Trump.[1] He previously worked in various positions in government consulting, including as a congressional staffer for U.S. Representative Tom Latham, and as an employee for CALIBRE Systems, and he also served as the executive director of the Republican Party of Florida.
Good. I like all of that. He may have very good connections in important places.
Peter O’Rourke will serve as our (NVAC) chairman of the board upon the effective date of the registration statement of which this prospectus is a part. Since December 2018, Mr. O’Rourke has served as Managing Partner at TCI Partners, a consulting firm focused on healthcare, aerospace and the public sector. From January 2017 to
December 2018 (2 years), Mr. O’Rourke served as the Acting Secretary and Chief of Staff of the Department of Veteran Affairs. From May 2015 to July 2016, Mr. O’Rourke served as a principal of Calibre Systems, Inc., a consulting firm. Mr. O’Rourke also served both U.S. Navy and Air Force. Mr. O’Rourke received a Bachelor of Arts in
Political Science from the University of Tennessee in Knoxville as well as a Master of Science in Logistics and Supply Chain Management from the United States Air
Force’s Institute of Technology. We believe that Mr. O’Rourke is well-qualified to serve as a director of our company based on Mr. O’Rourke’s consulting experience in
the healthcare industry.
Experience
Western Magnesium Corporation
Western Magnesium Corporation
1 year 5 months
President, U.S. Operations
Apr 2021 - Present1 year
Washington, District of Columbia, United States
Board Member
Nov 2020 - Present1 year 5 months
Veterans 4 America First Institute Graphic
President
Veterans 4 America First Institute
Aug 2021 - Present8 months
NorthView Acquisiton Corporation Graphic
Chairman of the Board
NorthView Acquisiton Corporation
Jun 2021 - Present10 months
New York, New York, United States
TCI Partners LLC Graphic
Manging Partner
TCI Partners LLC
Dec 2018 - Present3 years 4 months
Washington, District of Columbia, United States
AXIM Biotechnologies Graphic
Board Member
AXIM Biotechnologies
Jul 2020 - Present1 year 9 months
U.S. Department of Veterans Affairs
U.S. Department of Veterans Affairs
1 year 7 months
Acting Secretary
May 2018 - Jul 20183 months
Washington, District of Columbia, United States
Chief Of Staff
Feb 2018 - May 20184 months
Executive Director
Jan 2017 - Feb 20181 year 2 months
U.S. House of Representatives Graphic
Senior Policy Advisor
U.S. House of Representatives
2014 - 2014less than a year
Blackland Group, LLC Graphic
Vice President
Blackland Group, LLC
2012 - 20142 years
US Army Graphic
Program Manager
US Army
2010 - 2010less than a year
Accenture Graphic
Director
Accenture
2007 - 20092 years
Washington, District of Columbia, United States
George Group Consulting L P Graphic
Senior Consultant
George Group Consulting L P
2005 - 20072 years
United States Air Force Graphic
Commissioned Officer
United States Air Force
1998 - 20068 years
US Navy Graphic
Airman
US Navy
1990 - 19944 years
Education
Air Force Institute of Technology-Graduate School of Engineering & ManagementAir Force Institute of Technology-Graduate School of Engineering & Management Graphic
Air Force Institute of Technology-Graduate School of Engineering & Management
Master of Science - MS
University of Tennessee, KnoxvilleUniversity of Tennessee, Knoxville Graphic
University of Tennessee, Knoxville
Bachelor of Arts - BA
I like this guy!
He has quite a Resume.
Let's hope he can bring it to NorthView Acquisition Corp.!
Besides for the idea that I think this notice was supposed to go to members of Congress first instead of getting posted on the publicly accessible website, what is really f%&king annoying is how similar the product is to Immunopass:
https://www.megnahealth.com/products/#rapid-antibody-test
Granted, the EUA is for authorized laboratory use only (and not over-the-counter for retail use), but I seem to remember somewhere that Axim has a "patent pending" on exactly this type of test kit.....no?
How about this article:
https://finance.yahoo.com/news/veteran-owned-company-us-manufacturer-141100799.html
I am going to have to dive real deep for an explanation on this one...
I stopped looking at that FDA site when Axim moved its test kit "For Research Use Only", but interesting comment from a fairly regular critic here:
I think NVACR is the choice with the most potential for the biggest swing.
NVAC will determine where the values lie.
Let's assume NVAC goes to $12.50. That would mean that the % increase from $10 was 25%.
NVACW would then be worth $12.50 - $11.50 = $1. From .20, that is a 400% increase for this option.
NVACR would be worth $12.50/10 = $1.25. From .20, that would be a 525% increase for this option.
I guess time will tell.
Its like watching grass grow or paint dry.
Crickets.
I truly felt that Peter O'Rouke had a target picked out, having been on the Board at Axim and most probably having seen a few potential targets to acquire when Axim chose Sapphire Biotechnologies. I believe that Sapphire might have been the best suited for Axim at that time, but that Peter thought there were other promising targets that Axim just didn't have the capital to acquire.
Hence the reason for creating the SPAC.
Its now just over 3 months since the SPAC first went public (12/21/21). Maybe we just need one of those repetitious number dates, like 03/30/22, lol?
I'm certain, if an announcement was going to be made earlier, that the Military actions in the Ukraine would have delayed that announcement, but those actions are less and less in the news at this time.
Sure would be nice to finish off March Madness with a pps pop, or even something in the early Spring for that matter (April/May).
Let's see where things go.
I see this as a great move. Like spreading out tentacles. Can't hurt to have a Board member networked in with other Ophthalmologists, especially when the company you are on the Board of actually sells products that Ophthalmologists can use.
I'm certain that this new Network will fill up fast, and that the members of this association will share their trade secrets, experiences, AND PREFERRED PRODUCTS.
Truly a good place to introduce Axim's DED line of test kits.
When you are trying to get the most bang for the buck, this is like hitting the bullseye of your specific TARGET marketing.
Add another check mark to Axim's growing list of Kudos.
Unfortunately, I doubt this will translate into an increase in pps just yet.
Consider it another piece of straw added to the camel's back.
Sooner or later, all of these pieces will finally add up to the effect we are hoping for.
Godspeed.
Interesting.
"Vial operates a network of clinical trial research sites"
"Vial has officially expanded into Ophthalmology with the launch of the Vial Ophthalmology network"
As Vial continues to expand into new therapeutic areas, the mission to run clinical trials with faster execution and higher quality to bring new therapies to market, remains at the forefront of their efforts."
It looks like Vial is focused on cresting NETWORKS of professionals.
It can't hurt at all to have Dr. Tauber on the Board at Axim with a connection to a NETWORK of Opthamologists.
Seems to me to be a nice step forward in the right direction.
I'm a bit confused by what I believe you are saying, based on the following quote:
Another thought occurs to me:
Axim would probably have to invest a substantial amount of $ into getting an EUA for their Nabs test kit, because the RESEARCH linking levels of Nabs to immunity protection just doesn't exist...yet.
BUT, by putting the Nabs test kit out there for Research Use Only, Axim can get others to do the research they need, at no expense to Axim, and then when the time comes, Axim would just have to show that their test gives accurate results.
OTHERS would have done the research....using Axims test kits....to make the necessary correlation between Nabs levels and immunity.
Similar to the MMP-9 "walk through".
Let others do the work for you, using your test to get the results you need for the EUA or the 510(k)....
I'm betting there will be another late filing. No hurry to file a 10-K that doesn't have too much to say.
What really adds to my comfort level is that what I learn from feelers outside this board matches up to what I learn here as well.
In particular, I was able to determine (outside of this board) that the MJNA related team of investors are "solid" with Axim. "Selling" pressure is certainly not coming from there.
It appears to me that AXIM has a good foundation of investors. I'm once again guessing the selling pressure is predominantly coming from those who were here for the big pop expected upon EUA. As that now seems like a distant hope, those shares are being shed. It shouldn't be too much longer before we are left with those who have their eyes (pun intended) on the DED line. Those share holders will be holding, knowing that the DED line performance won't really take hold for at least another 6 months.
Once the EUA hopefuls are gone, volume should settle down, and pps should level off and start heading back in the right direction.
I myself am keeping the faith.
I believe Axim has good leadership, motivation, great products, and a huge amount of potential.
Axim is just going to have to continue to limp along until the rest of the OTC market starts to recognize those attributes.
Godspeed all.
BTW, my friend's daughter is quite knowledgeable in her field.
The new MMP-9 test kit can not only be used for determining DED, but since it detects proteins associated with inflammation, the test kit can also be used to determine any improvement in DED, and more importantly, as a pre-test before any planned eye surgeries.
In other words, this new test kit has even more usefulness than the original two. Furthermore, since MMP-9 has already been medically proven and accepted to be an indicator of inflammation, the application for a 510(k) should only require "comparison studies".
Basically, Axim should merely have to prove that their test is accurate in determining MMP-9 levels. The rest of the application process has already been done for them by other companies. All of the "competition" don't have the ability to give results in 10 minutes (the other tests require that the samples be sent out to a lab), so this third test could be considered "First in Class" as well.
Axim should be able to "walk right through" the approval process.
If Axim can get those first two DED line test kits generally accepted by the ophthalmology community (which I'm guessing is their goal at this time), then that third kit would have a built in market just waiting for it, and that MMP-9 kit could be available before the end of this year.
Would be nice to see some of these achievements translate into an increase in the pps.
Thanks, helpful.
With MJNA trading at .01 to .02, 3.4 billion + shares outstanding, I don't think they are in a position to acquire AXIM. They would need a huge amount of cooperation from Management, and on every level (Axim just beginning to fly, Axim got out of the Cannabis industry years ago, all the potential in the DED line, Cancer line, and patented rapid result test kit technology, etc.) I don't see John wanting to turn over the reigns any time soon.
Where Axim is right now is what your average entrepreneur spends years working towards. The party is just getting started.
Again, thanks for the input. Very helpful as a starting point in our conversation. I'm not sure where this will lead, but everything is worth a shot.
Lol, no.
The guy's daughter is an opthamologist and is going to evaluate the DED line of products as soon as the opportunity presents itself. If she gives a thumbs up to the products, he will belly up with a quite serious investment.
But he is curious to know where the
current selling pressure is coming from.
I figured perhaps Blue might have an idea as to what MJNA has been doing with all their shaees.
One of these days, this BlindSquirrel will find a nut...
Problem with that theory is that we are seeing SELLING pressure.
If insiders were buying, demand would be up and the price would be headed North.
I'm out to dinner with a not so small interested investor, so I'm hoping someone can give me a quick, reasonable answer to the following:
How many shares does MJNA currently hold?
AND/OR, does anyone have a reasonable guess as to where the selling pressure shares might be coming from?
I'm with Dean on this one.
So many who have invested in AXIM in the past are now allowing the very low pps to blind them to the accomplishments that Axim has had to date.
When you set your goals (ie: the bar) high, or extremely high, and you fail to achieve them, that is not indicative of failure.
FAILURE occurs when you give up altogether.
The EUA for Immunopass would have been an instant game changer for Axim. That was reaching for the stars so far out that those stars weren't even in this galaxy but rather in the next galaxy over.
But when that was clearly not going to happen at this time, Axim immediately got back in the saddle (forgive me for mixing metaphors) and re-directed the sale of its Nabs test kits to the Research Market Only, which, in all honesty, is the proper and best place for it at this time
There is a hell of a lot of research that needs to be done right now to come up with conclusive and reproducible results regarding the Covid-19 virus, natural immunity, and the various vaccines and number of dosages necessary to meet certain Nabs levels, and what those levels mean, etc.
And Axim's rapid, inexpensive, and accurate Nabs test kit(s) are perfectly suited to help research achieve results, easily, and sooner rather than later.
FAILURE would have been ditching the Nabs test altogether, but the Axim team didn't do that.
If you actually look at what Axim has achieved over the past 6 months, you can see that the progress does not align with the movement of the pps.
Yes, taking advantage of this bargain pps is great for those who can understand the profound steps forward that the company has realized over the last half year, but it is not for those who can't see the forest for the trees.
I'm with Dean.
I would prefer to see the pps gradually rise over the next 6 to 8 months (following along with Axim's progress) and forego the ability to pick up super cheap shares.
I am just hoping that hose who are selling are the ones who were holding out for the EUA, and that what will soon be left are those who have put their sights on the success of the DED line.
Once the DED line starts to produce results, we should then see the pps follow along with the strides that Axim is making.
https://www.marketscreener.com/quote/stock/NORTHVIEW-ACQUISITION-COR-132254317/news/NORTHVIEW-ACQUISITION-CORP-MANAGEMENT-S-DISCUSSION-AND-ANALYSIS-OF-FINANCIAL-CONDITION-AND-RESULTS-39801027/
There was a news item yesterday that did add value slightly to all three of the issuances by NorthView:
NVAC 4,816 $9.84 +.20%
NVACR 26,407 $.1499 +7.07%
NVACW 181,950 $.169 +.06%
It was the issuance of the 10-K for 2021.
Key Notes from that 10-K are that the company is searching for an acquisition target, has monthly office space rent and secretarial expenses of $5,000 per month (renting space from one of the directors), and that the company believes it has sufficient cash reserves to cover needs for 1 year or consummation of a business acquisition, whichever comes first. See highlights from the report below:
I do like that one of the sponsors put up the initial capital to form the SPAC (about a quarter of a million dollars). This has been paid back.
Good point, but I find what the re-financing says about the condition of the company more important than the actual terms.
Insiders putting up their own $s to payoff toxic debt.
Insiders know best where the company is at, and where it intends to go.
Their commitment, although not providing absolute guarantees, certainly speaks volumes.
Axim has a long way to go, but they do appear to be moving in the right direction, and I do believe that their progress will soon be picking up the pace.
If you are not seeing "material results", then it is just your definition of material results that might be too demanding.
Not hitting goals or targets by certain dates probably happens in every situation out there, more often than not.
Setting goals higher than can be easily achieved is what motivates those involved to strive at 110%.
Set your goals high.
Reach for the stars, not the moon.
I, myself, do have confidence in management. John H has acquired two ready to go (ie: 510(k) approved) DED test kits, recently added a third future kit to that line, and probably put together a DED Board consisting of some of the most talented Ophthalmologist experts in the field.
If, after seeing what happened when Empowered screwed up and sold 2,100 Immunopass test kits before getting approval to do so, John H decided to be more cautious and put the manufactured DED test kits to practice before going to market (in order to work out any bugs), then that decision would, in my opinion, appear prudent.
An ounce of prevention is worth a pound of cure.
...and, even when there wasn't a pound of cure available for the Empowered mess-up, John H quickly shifted direction to an entirely new approach and moved the Nabs test kits to market via Research Use Only.
Rare to see a company be able to recover so quickly; Nice to see management is able to "spin on a dime."
I would say a lot of material things have happened these past few months. Certainly, things are moving forward, although not as quickly as anyone would have hoped (which, as mentioned earlier, happens more often than not).
Although I too would prefer to see Axim hit its goals (and beyond), I believe that in the long run, it is better to slow down and get things right the first time through, rather than to have to figure out how to recover from one's mistakes.
By the way, the trademark "Immunopass" is entirely owned by Empowered. Therefore, by completely cutting ties with Empowered, Axim could apply for an EUA or a 510(k) from the FDA with minimal residual negativity attached to their Nabs test kit.
This is similar to what happened after the Exxon Valdez oil spill (March 24, 1989), when all the oil companies immediately stopped using their own tankers to transport oil.
Now, when there is an unfortunate oil spill, the negative publicity doesn't carry over to the actual oil company itself.
I don't know if it was luck or foresight, but the way things worked out, Axim Biotechnologies was very fortunately protected/shielded/spared from any fallout associated with the Empowered-Immunopass disaster.
Management might deserve more "confidence" then they are currently getting credit for.
Would be nice to see AXIM trading above 50 cents once again...
Personally I don't believe that the military actions in the Ukraine are affecting Axim's pps to any great extent.
More likely it is the loss of hope of an EUA that will be keeping the pps down for the next few months.
The light at the end of the tunnel should be sales of the DED line and sales of the Nabs assay test kits for Research Use Only, both of which won't be visible until the 2nd quarter 10-Q, due out on August 15th (5 months from now).
Quite a long wait (5 months) for anyone who was hoping for a nice pop in the near future, but I still believe it will prove worthwhile in the end.
Behind the scenes, great things are happening at Axim:
1. There are 2 DED test kits going to market soon (for use as diagnostic tools by medical professionals, ie: ophthalmologists)
2. The Nabs tests have been redirected to being marketed to the research market, which is where Axim's Nab test should prove extremely useful, as the test kits are very accurate and give immediate results. This at a time when the entire world is anxious to discover how effective natural immunity is, how the different vaccinations, combinations, and number of shots given effect immunity, how long immunity lasts, and how any combination of all of these factors as well as others have been on the creation of Nabs - and what those Nabs levels translate into. There is a hell of a lot of research work to be done, and Axim's test kits are ideal for helping research much more rapidly come to their results and sort this all out.
3. Axim has not given up the idea of using its Nabs test kits in medical fields and/or the retail market
I verified your findings. You are correct. Empowered owns the trademark, "Immunopass", but I do wonder what the following means on 11-18-2021 of your finding?:
Yup, and if you think the actions in the Ukraine are stalling any acquisition announcements, I wonder what will happen when China goes into Taiwan...
It looks ike it might be a long wait.
All very interesting points.
Apparently, what is being sold "for Research Use Only" (RUO) is not called "Immunopass".
From this statement, "Looking at Quantitative EUA per FDA", it looks like there still is a glimmer of hope (at some future date) for "Immunopass" to get an EUA from the FDA and to be sold to the public.
I'm guessing "Immunopass" is the brand name being reserved for some future date, when the test kit is (finally) approved for retail sales.
But in the meantime, Axim is looking to sell something from the Nabs line of test kits in order to get some revenues, and perhaps more importantly, to get the fundamental idea of "Immunopass" out there.
Maybe there is another "Manufacturing Partner" (MP) somewhere that is willing to pick up where Empowered left off, learn from their mistake(s), and get Immunopass past the goal line..
Perhaps even that MP could be stumbled upon via the RUO market?
Although the departure from Empowered may appear premature, I think it was absolutely necessary at this time in order for Axim to distance themselves from the "bad blood" between Empowered and the FDA.
Seriously speaking, the FDA pulled a fast one. Empowered had realized their mistake and voluntarily issued their own recall back in December.
I think the FDA's harshest level of recall that they announced over a month later was very literally overkill, but the regulator is all powerful, and their decisions and Press Releases are not to be questioned.
Axim had to cut ties to Empowered in order to move on, or Axim would have been stuck in the mud alongside Empowered while Empowered fought to get off the FDA's Schiff list (which could take months, years, or even never).
Rest assured, if that very slim chance were to occur, John would not pass up the opportunity.
Above all else, he is a business man with the primary goal of seeing Axim succeed.
But I think it is a very slim chance, as I now fully believe the FDA was looking for an excuse to delay the EUA for Immunopass as long as possible.
I think the underlying problem is that Immunopass would give the power to make your own health decisions back to the people, and that the FDA used the lack of enough research evidence linking a certain Nab level to resistance levels as their reason for their hesitance.
In other words, there isn't yet enough research to suggest that levels of Nabs above X amount will provide a Y level of protection.
That is why Immunopass is now being sold for Research Purpose Only - so that enough clinical trials can be done and their results compared in order to create some kind of a definitive result.
Simply put, the FDA figured if the public had an easy way of determining their Nab levels, they might use those levels as an excuse not to get another Pfizer shot, or as ammunition to build a protest against the already weakening arguments for vaccination and masks.
Politics. There is still way too much money to be made by those corrupt individuals in charge for every extra jab that gets injected.
...but rest 100% assured, in the extremely slim chance that Empowered did get an EUA or an approval in EU or CA, neither John H or Empowered would pass up the opportunity at having "a loaf of bread under each arm, and their asses in tubs full of butter."
Exactly 1 week later, 5 shares of NVAC traded hands today for a total of $49.02
I still feel everyone has their shares and are holding, waiting for the announcement of the acquisition target.
Keeping in mind that there are big players, such as Yakira Capital Management with $10 million (1 million shares) and Skyview Investment Advisers, LLC. with $2 million (200,000 shares), I still feel pretty confident that NorthView is going to have to perform or risk disappointing...and soon.
I further believe that the activities in the Ukraine are stalling the announcement of the acquisition, as no one wants to see such an important Press Release being over shadowed by 24/7 coverage of the war going on over there.
Hopefully the 2 nations can come to some kind of a peace agreement in the very near future, and that we can get a resolution there with a long enough break for the announcement before China begins the next crisis in Taiwan.
It is sad that so many have been waiting for this opportunity (weak and feeble leadership at the top ranks of the United States), and that Biden and Kamala (et al) have given them just what they were looking for.
Fortunately, Trump is standing by, ready to restore this country to its original greatness, but don't expect too much salvation until the Great Red Sweep (aka, The Red Tsunami) on November 8th.
It is going to be a long, drawn out summer.
I am seeing good things for AXIM coming down the road, but not nearly as amazing as I once thought. Still good, though.
Axim has completely (100%) severed its ties with Empowered, so there is no expectation of anything from the EU or CA either. Sadly for Empowered, Empowered is now on the FDA's permanent Schiff List. Empowered most likely will never be able to obtain an EUA or even a 510(k) for anything ever again. I'm guessing Empowered failed miserably at "pay to play." So goes the politics of the Present Politically Corrupt Party in Charge (PPCPIC).
Axim presumably (as per their website) would still be interested in pursuing an EUA in the US for retail (diagnostic) purposes, and approvals in CA and the EU as well, but only if - as was the case with Empowered - another manufacturing partner were to come along and foot all the expenses necessary to make that happen (as did Empowered). Unfortunately, after having seen the (unfair?) beating Empowered was handed down by the FDA, I personally don't think anyone is going to jump on that sword any time soon.
Axim is now marketing Immunopass as "Research Use Only" (RUO), which enables Axim to sell Immunopass immediately, and at a much higher price per unit. Retail sales would have had to be about $12-$15 per unit in order to be successful. Research use, on the other hand, has a much higher mark-up and the ability to pay much more (2 1/2 to 3 1/2 times as much), since the features associated with Immunopass still beat all of its competitors hands down. Of course, the number of kits for RUO will only be a fraction of what Axim would have seen had they gotten their EUA, but the premium ("profit" per test kit) will be greater. Still a huge plus for Axim, but not nearly what we were hoping for.
As for the DED line, it looks like the two approved test kits are being used presently to work out any of the bugs before going to market, so I am now guessing sales (and revenues from sales) won't begin showing up till Q2.
I recently spoke with someone familiar with 510(k)s, and the newest test (the one that detects the biomarker MMP-9) could very well get 510(k) approval this year, since the research and the link between MMP-9 and DED have already been conclusively established. (The biggest problem with Immunopass was that there wasn't any conclusive research out there as of yet that could precisely establish the level of Nabs necessary to prevent infection!).
So there is the possibility and potential that the newest DED test kit also could hit the market before the end of this year.
The DED line is definitely now Axim's primary product line, and Axim is truly doing an amazing job at accumulating the world renowned talent to make this line a success.
Bottom Line: With the expectation and hopes of an EUA from the FDA being removed, that part of the high risk/high reward equation is gone as well. Any short-term investment in Axim should be made with respect to their (much less risky) DED line, with Immunopass Research Use Only sales being considered a small added plus, and the cancer line being considered for its long term potential.
?
What am I missing?
Q1 2022 ends in just over 3 weeks, and the 10-Q won't be out till May 15.
The expected sales launch I quoted was for the DED line, the 2 tests that are already 510(k) approved by the FDA. From a previous PR, I believe these test kits are being manufactured in Spain.
Are you suggesting that the sale of these test kits has not yet begun or won't begin over the next 3 weeks?
As for Immunopass, with no FDA approval needed and "Now Available", are you further suggesting that there won't be any RUO sales of Immunopass in the next 3 weeks?
Axim has updated its web page for Immunopass:
https://aximbiotech.com/science/covid-19-diagnostic-research/
Key Notes:
What happens now with the Immunopass approvals sought for EU and Canada?
Are we to assume that those too, as well as the FDA EUA, are no longer being sought?
I know at first thought one might think, "of course", but keep in mind that things approved in the EU and CA aren't necessarily approved in the US (case in point: CovClear).
Any thoughts?
Yes, just running sideways, waiting for the acquisition target announcement.
Today:
NVAC = 17,556 shares @ $9.80 = $175,000 (average volume is 12.6 times larger)
NVACW = 10,300 @ .1588 = $1,636.00
NVACR = 2,437 @ .1494 = $365.00
I still think we will need the Russian invasion of Ukraine to quiet down before a target company is announced.
I now hope to hear by April 22nd.
Godspeed.
Interesting...
I am seeing the same thing. Axim had a quantitative test, then the FDA wanted it to be qualitative and they complied, now it is back to quantitative...
Further proof that the FDA has absolutely no idea what it is doing. I'd classify this as an abuse of its power, not uncommon in the bureaucracy of today.
It seems like the FDA is fearful of putting a result (either qualitative or quantitative) on a test for at home use, for fear that the result might "mislead" an individual into believing they are protected from COVID (?)
At any rate, switching to "Research Use Only" is a good "lift and shift" approach for John H. to do at this time.
The EUA for at home use has been stalled for way too long.
Might as well go for what I believe should be a much easier to attain EUA for Immunopass for "Research Use Only", rather than the much more complicated and elusive "For Diagnostic purposes" EUA that they were seeking.
Bottom line: The FDA is fearful of making a commitment to the presence of a certain level of neutralizing antibodies as being indicative of a level of protection from COVID-19, especially since they just came off 2 years of BS "following the science" when it came to vaccinations and masks.
I guess NOW the scientific research just isn't there yet.
"Follow the science", when it comes to antibody levels and results in the hands of the people in order to make their own health decisions, just doesn't fit in with the political agenda at this time.
Good move by John H., though, I must say! This is a less lucrative but much easier way to get Immunopass to market, and it enables the science to use Immunopass to figure out more definitively what levels of antibodies offer what levels of protection.
If nothing else, it is a good introduction in order to get Immunopass out there and into the hands of the scientific and healthcare industries.
At home use can ultimately be sought at a later date.
A series of small baby steps, rather than the huge leap to success that John H. was going for.
...I just wish Axim had come to this (apparently inevitable) understanding/conclusion months ago...
I don't think an annual fee of $5,672 is anything to be concerned about.
Truly the very least of Axim's worries.
When it comes to the DED line, I believe John H. has that well under control, and it is just a matter of time before the revenues start to flow and the increase in pps follows.
I believe DED line revenues will begin this month (March 2022) and will show on the Q1 10-Q (due out May 15), but won't be anything to speak of (I'm guessing no more than $50,000). Q2 would see that move more into the low 100s of thousands, Q3 into the millions, and by end of year into the 10s of millions.
Just my gut feeling, nothing more, and if I am wrong, it won't be the first time (but even a Blind Squirrel finds a nut every once in a while).
Lately I have seen more and more Dry Eye Disease Commercials from Novartis:
https://www.fiercepharma.com/marketing/novartis-introduces-inflammation-villain-character-its-first-xiidra-dry-eye-dtc-campaign
Truly perfect timing for Axim to come out with its patented, 10 to 15 minute results, inexpensive, easy to use by physicians (requires the collection of a tear drop), etc. test kits.
Axim's DED line of test kits are going to revolutionize the diagnostics of DED and cut the cost to physicians dramatically, as well as enable the physician to give a definitive diagnosis right then and there, in the doctor's office, rather than have to wait days for laboratory results.
That is what is meant by "light years ahead of industry competitors" in the following quote from the most recent (February 15th) Press Release:
I don't think I have seen a single share of NVACR trade in the last 2 days, not since the 2 shares that traded on Wednesday.
Shares of NVAC appear to have been ALL buys today (99,756).
So too can be said of NVACW (ALL buys), 247,871
Looks like things are leveling off off and going to travel sideways for a while until things get stirred up by the announcement of an acquisition target.
Yakira Capital Management = $10 million.
Skyview Investment Advisers, LLC. $2 million.
...as of 12/31/2021
Based on the latest Press Release of February 15:
https://www.globenewswire.com/news-release/2022/02/15/2385339/33692/en/AXIM-Biotech-Announces-New-Milestones-in-Preparation-of-Dry-Eye-Disease-Diagnostics-Launch.html
I would like to believe that we will see the onset of revenues from the DED test kits in the 1st quarter 10-Q, certainly by the 2nd quarter.
Your summary as follows:
Project Veritas completely exposed the FDA for illegally colluding with vaccine makers.
— Kαƚყ🕊🌻🎨 (@Katy30770035) February 16, 2022
The FDA responded by lying and saying it isn't their employee. pic.twitter.com/bAQg1SrTWb